SCHEMBL1333941

SCHEMBL1333941

CC(C)(C)Oc1ccc(-c2cnc(N[C@H]3CC[C@H](C)CC3)nc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.38
GABBR2 O75899 1/20 0.37
GABBR1 Q9UBS5 1/20 0.37
MAPK10 P53779 2/20 0.37
JUN P05412 1/20 0.37
CD38 P28907 1/20 0.36
MAPK6 Q16659 4/20 0.35
MAPK1 P28482 1/20 0.35
ALDH1A1 P00352 1/20 0.34
RIPK1 Q13546 1/20 0.34
ABL1 P00519 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
SYK P43405 1/20 0.34
MAPK8 P45983 3/20 0.34
MAPK9 P45984 2/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1333940 1.00 GRM5 (0.41) GRM5IRAK4GABBR2GABBR1MAPK10
SCHEMBL1333238 0.88 GABBR2 (0.49) GRM5IRAK4GABBR2GABBR1ADORA2A
SCHEMBL1333239 0.88 GABBR2 (0.49) GRM5IRAK4GABBR2GABBR1ADORA2A
SCHEMBL12127078 0.88 GABBR2 (0.49) GRM5IRAK4GABBR2GABBR1ADORA2A
SCHEMBL1032531 0.85 MAPK6 (0.47) GRM5IRAK4MAPK6ADORA2ADRD2
SCHEMBL1032533 0.85 MAPK6 (0.47) GRM5IRAK4MAPK6ADORA2ADRD2
SCHEMBL1033459 0.82 PTGS1 (0.41) GRM5IRAK4GABBR2GABBR1ALDH1A1
SCHEMBL1033458 0.82 PTGS1 (0.41) GRM5IRAK4GABBR2GABBR1ALDH1A1
SCHEMBL1334209 0.82 GRM5 (0.41) GRM5IRAK4MAPK10JUNCD38
SCHEMBL1334210 0.82 GRM5 (0.41) GRM5IRAK4MAPK10JUNCD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS GRM5 2764/4885IRAK4 542/4885GABBR2 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.